Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–90.
Jagsi R, Pottow JA, Griffith KA, Bradley C, Hamilton AS, Graff J, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32(12):1269–76.
Arozullah AM, Calhoun EA, Wolf M, Finley D, Fitzner KA, Heckinger EA, et al. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol. 2004;2(3):271–8.
Pisu M, Azuero A, Benz R, McNees P, Meneses K. Out-of-pocket costs and burden among rural breast cancer survivors. Cancer Med. 2017;6(3):572–81.
Pisu M, Azuero A, Meneses K, Burkhardt J, McNees P. Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI). Breast Cancer Res Treat. 2011;127(2):521–9.
Pisu M, Azuero A, McNees P, Burkhardt J, Benz R, Meneses K. The out of pocket cost of breast cancer survivors: a review. J Cancer Surviv. 2010;4:202–9.
Oatis W, Nonzee N, Markossian T, Shankaran V, McKoy J, Evens A, et al. Interpreting out-of-pocket expenditures for cancer patients: the importance of considering baseline household income information. J Clin Oncol. 2009;27(15S):6541.
Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109(2):367–77.
Vyas A, Madhavan SS, Sambamoorthi U, Pan XL, Regier M, Hazard H, et al. Healthcare utilization and costs during the initial phase of care among elderly women with breast cancer. J Natl Compr Cancer Netw. 2017;15(11):1401–9.
Pisu M, Henrikson NB, Banegas MP, Yabroff KR. Costs of cancer along the care continuum: what we can expect based on recent literature. Cancer. 2018;124(21):4181–91.
Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP Jr. Productivity costs associated with breast cancer among survivors aged 18–44 years. Am J Prev Med. 2016;50(2):286–94.
Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007;12(4):478–83.
Schnur JB, Zivin JG, Mattson DM Jr, Green S, Jandorf LH, Wernicke AG, et al. Acute skin toxicity-related, out-of-pocket expenses in patients with breast cancer treated with external beam radiotherapy. Support Care Cancer. 2012;20(12):3105–13.
Barber B. Economic burden of toxicities associated with treating metastatic melanoma in the United States.
Irwin DE, Masaquel A, Johnston S, Barnett B. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries. J Med Econ. 2016;19(11):1027–33.
Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014;3(1):259.
Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou Z-Y, Viau DL, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014;19(9):901–8.
Rashid N, Koh HA, Baca HC, Lin KJ, Malecha SE, Masaquel A. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer: Targets and Therapy. 2016;8:173.
Shih Y-CT XY, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27(12):2007–14.
Schmitz KH, DiSipio T, Gordon LG, Hayes SC. Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of care. Support Care Cancer. 2015;23(6):1807–17.
Dean LT, Schmitz KH, Frick KD, Nicholas LH, Zhang Y, Subramanian S, et al. Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. J Cancer Surviv. 2018;12(3):306–15.
Boyages J, Xu Y, Kalfa S, Koelmeyer L, Parkinson B, Mackie H, et al. Financial cost of lymphedema borne by women with breast cancer. Psycho-Oncology. 2017;26(6):849–55.
Norman SA, Localio Ar PSL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27(3):390–7.
Paskett ED. Symptoms: lymphedema. In: Ganz PA, editor. Improving outcomes for breast cancer survivors. Cham, Switzerland: Springer International Publishing AG; 2015. p. 101–13.
American Cancer Society. Cancer treatment and survivorship facts and figures 2016–2017. Atlanta, GA:2016.
Mortimer PS. The pathophysiology of lymphedema. Cancer. 1998;83:2798–802.
Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368–77.
Bernas M. International Society of Lymphology Executive Committee, the diagnosis and treatment of peripheral lymphedema-draft revision of the 1995 consensus document of the international society of lymphology executive committee for discussion at the September 3-7, XVIIIth international congress of lymphology in Genoa, Italy. Lymphology. 2001;34(2):84–91.
Dean LT, Kumar A, Kim T, Herling M, Brown JC, Zhang Z, et al. Race or resource? BMI, race, and other social factors as risk factors for interlimb differences among overweight breast cancer survivors with lymphedema. J Obes. 2016;2016(8241710).
Dean LT, Moss SL, Ransome Y, Frasso-Jaramillo L, Zhang Y, Visvanathan K, et al. “It still affects our economic situation” Long-term economic burden of breast cancer and lymphedema. J Support Care Cancer. 2018;27:1–12.
Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith R, et al. Weight lifting for women at risk for breast cancer–related lymphedema: a randomized trial. Jama. 2010;304(24):2699–705.
Schmitz KH, Troxel AB, Cheville A, Grant LL, Bryan CJ, Gross CR, et al. Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors. Contemp Clin Trials. 2009;30(3):233–45.
Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, et al. The Women In Steady Exercise Research (WISER) Survivor trial: the innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. Contemp Clin Trials. 2017;61:63–72.
Schmitz KH, Troxel AB, Dean LT, De Michele A, Brown JC, Sturgeon K, et al. Effect of home-based exercise and weight loss programs on breast cancer–related lymphedema outcomes among overweight breast cancer survivors: The WISER Survivor randomized clinical trial. JAMA Oncol. 2019; [in press].
Patterson RE, Colditz GA, Hu FB, Schmitz KH, Ahima RS, Brownson RC, et al. The 2011–2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design. Cancer Causes Control. 2013;24(4):695–704.
Patton MQ. Qualitative evaluation and research methods. Thousand Oaks: SAGE Publications, inc; 1990.
Berkman L, Macintyre S. The measurement of social class in health studies: old measures and new formulations. IARC Sci Publ. 1997;138:51–64.
Goossens M, Rutten-van Molken M, Vlaeyen J, van der Linden S. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53(7):688–95.
Van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835–45.
US Bureau of Labor Statistics. National occupational employment and wage estimates, United States. http://www.bls.gov/oes/current/oes_nat.htm.
Grosse SD, Krueger KV, Mvundura M. Economic productivity by age and sex: 2007 Estimates for the United States. Med Care 2009:S94-S103.
US Bureau of Labor Statistics. Consumer Price Index. http://www.bls.gov/cpi/data.htm.
Oberst K, Bradley CJ, Schenk M. Breast and prostate cancer patient’s reliability of treatment reporting. J Registry Manag. 2008;36(1):12–5.
Brown ML, Yabroff KR. Chapter 12: Economic impact of cancer in the United States. In: Fraumeni J, Schottenfeld D, editors. Cancer epidemiology and prevention. Oxford: Oxford University Press; 2006. p. 202–16.
Creswell JW, Plano Clark VL, Gutmann ML, Hanson WE. Advanced mixed methods research designs. In: Handbook of mixed methods in social and behavioral research, vol. 209; 2003. p. 240.
Ivankova NV, Creswell JW, Stick SL. Using mixed-methods sequential explanatory design: from theory to practice. Field Methods. 2006;18(1):3–20.
Zafar SY, Newcomer LN, Jusfin McCarthy J, Nasso SF, Saltz LB. How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. ASCO educational book. 2017;37:35–9.
Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370.
National Research Council. From cancer patient to cancer survivor: lost in transition. Washington, D.C: National Academies Press; 2005.
Dean LT, Moss SL, Rollinson SI, Frasso-Jaramillo L, Paxton RJ, Owczarak JT. Patient recommendations for reducing long-lasting economic burden after breast cancer. Cancer. 2019;125(11):1929–40.
Weiss R. Cost of a lymphedema treatment mandate-10 years of experience in the Commonwealth of Virginia. Heal Econ Rev. 2016;6(1):42.
Lymphedema Treatment Act: background & history. http://lymphedematreatmentact.org/about-the-bill/background-information/. Accessed 3 Oct 2017.
Cliff BQ, Rozier M, Fendrick AM. Health insurance benefits should be equitable, not necessarily equal. health affairs blog: Health Equity2017.